Infudopa SubC

About Dizlin Pharmaceuticals

Dizlin Pharmaceuticals is a private, pre-revenue biotech founded in 2003 (incorporated 2015) developing next-generation infusion therapies for advanced Parkinson's disease. Its lead assets, Infudopa SubC™ and Infudopa IntraV™, are stable liquid formulations of levodopa/carbidopa designed to provide continuous drug delivery, aiming to reduce debilitating 'on-off' symptoms. The company leverages academic collaborations and has entered a strategic global co-development agreement with Neuraxpharm, positioning it to advance its pipeline through partnership rather than building commercial infrastructure internally.

Therapeutic Areas